The somatic mutations in Interferon-γ signal molecules in human uterine leiomyosarcoma by Hayashi, Takuma et al.
Commentry
Biomedical Genetics and Genomics 
Biomed Genet Genomics, 2016         doi: 10.15761/BGG.1000126  Volume 2(1): 1-5
ISSN: 2398-5399
The somatic mutations in Interferon-γ signal molecules in 
human uterine leiomyosarcoma
Takuma Hayashi1,9*, Tomoyuki Ichimura2, Mari Kasai2, Hirofumi Ando1, Koichi Ida1, Miki Kawano3, Tanri Shiozawa1, Susumu Tonegawa4,5, 
Yae Kanai6,10, Hiroyuki Aburatani7, Nobuo Yaegashi8 and Ikuo Konishi9 
1Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Japan
2Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Japan
3Department of Health Science, Kyushu University Graduate School of Medicine, Japan
4Picower Institute, Massachusetts Institute of Technology, USA
5Pathology Division, Keio University School of Medicine, Japan 
6The Cancer System Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Japan
7Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Japan, 
8National Hospital Organization Kyoto Medical Center, Japan
9Promoting Business using Advanced Technology, Japan Science and Technology Agency (JST), Japan, 
10The International Human Epigenome Consortium (IHEC) and CREST, Japan Science and Technology Agency (JST), Japan
Abstract
Human uterine leiomyosarcoma (U-LMS) is neoplastic malignancy that typically arises in tissues of mesenchymal origin. The identification of novel molecular 
mechanism leading to human U-LMS formation and the establishment of new therapies has been hampered by several critical points. We earlier reported that mice 
with a homozygous deficiency for proteasome beta subunit 9 (Psmb9)/β1i, an interferon (IFN)-γ inducible factor, spontaneously develop U-LMS. The use of research 
findings of the experiment with mouse model has been successful in increasing our knowledge and understanding of how alterations, in relevant oncogenic, tumour 
suppressive, and signaling pathways directly impact sarcomagenesis. The IFN-γ pathway is important for control of tumour growth and invasion and has been 
implicated in several malignant tumours. In this study, experiments with human tissues revealed a defective expression of PSMB9/β1i in human U-LMS that was 
traced to the IFN-γ pathway and the specific effect of somatic mutations of JANUS KINASE ( JAK) 1 molecule or promoter region on the locus cording PSMB9/
β1i gene. Understanding the molecular mechanisms of human U-LMS may lead to identification of new diagnostic candidates or therapeutic targets against human 
U-LMS.
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Human uterine leiomyosarcoma (U-LMS) is neoplastic malignancy 
that typically arises in tissues of mesenchymal origin. The identification 
of novel molecular mechanism leading to human U-LMS formation 
and the establishment of new therapies has been hampered by several 
critical points. We earlier reported that mice with a homozygous 
deficiency for proteasome beta subunit (Psmb)9/β1i, an interferon 
(IFN)-γ inducible factor, spontaneously develop U-LMS. The use 
of research findings of the experiment with mouse model has been 
successful in increasing our knowledge and understanding of how 
alterations, in relevant oncogenic, tumour suppressive, and signaling 
pathways directly impact sarcomagenesis. The IFN-γ pathway is 
important for control of tumour growth and invasion and has been 
implicated in several malignant tumours. In this study, experiments 
with human tissues revealed a defective expression of PSMB9/β1i in 
human U-LMS that was traced to the IFN-Γ pathway and the specific 
effect of somatic mutations of JANUS KINASE (JAK) 1 molecule or 
promoter region on the locus cording PSMB9/β1i gene. Understanding 
the molecular mechanisms of human U-LMS may lead to identification 
of new diagnostic candidates or therapeutic targets against human 
U-LMS. 
Uterine mesenchymal tumours have been traditionally divided 
into benign tumour leiomyomas (LMA) and malignant tumour 
leiomyosarcomas (LMS) based on cytological atypia, mitotic activity 
and other criteria. Uterine LMS (U-LMS), which are some of the most 
common neoplasms of the female genital tract, are relatively rare 
uterine mesenchymal tumour, having an estimated annual incidence of 
0.64 per 100,000 women [1]. They account for approximately one-third 
of uterine sarcomas, of only 53% for tumours confined to the uterus 
[2,3]. Generally, patients with U-LMS typically present with vaginal 
bleeding, pain, and a pelvic mass. Gynecological tumour, for instance 
breast cancer and endometrial carcinomas, are strongly promoted 
by female hormones, but the rate of hormone receptor expression 
is reported to be significantly less in human U-LMS compared with 
normal myometrime. These low expressions of receptor were found to 
not correlate with the promotion of initial disease development or with 
the overall survival of patients with U-LMS.
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As U-LMS is resistant to chemotherapy and radiotherapy, and thus 
surgical intervention is virtually the only means of treatment for this 
disease, however, molecular targeting therapies against tumours have 
recently shown remarkable achievements [4-8]. It is noteworthy that, 
when adjusting for stage and mitotic count, LMS has a significantly 
worse prognosis than carcinosarcoma; developing an efficient adjuvant 
therapy is expected to improve the prognosis of the disease [9]. A trend 
towards prolonged disease-free survival is seen in patients with matrix 
metalloproteinase (MMP)-2-negative tumours [10]. Although typical 
presentations with hypercalcemia or eosinophilia have been reported, 
this clinical abnormality is not an initial risk factor for U-LMS. To the 
best of our knowledge, little is known regarding the biology of U-LMS; 
therefore, the risk factors that promote the initial development of 
U-LMS and regulate their growth in vivo remain poorly understood.
The mice with a targeted disruption of proteasome beta subunit 
9 (PSMB9)/β1i, which is interferon (IFN)-γ-inducible proteasome 
subunit, exhibited a defect in tissue- and substrate- dependent 
proteasome function, and female PSMB9/β1i-deficient mice shown to 
develop U-LMS, with a disease prevalence of 37% by 14 months of age 
[11,12]. Defective expression of PSMB9/β1i is likely to be one of the 
risk factors for the development of human U-LMS, as it is in PSMB9/
β1i-deficient mice [12]. Recent report shows that stable PSMB9/β1i 
expression contributes to cell proliferation, which directly correlates 
to the progressive deterioration with increasing stage and grade of the 
tumour. As the importance and involvement of the IFN-γ pathway in 
the activation of shared-promoter of the transporter associated with 
antigen processing (TAP) 1 and PSMB9/β1i have been established, 
it is demonstrated that the defective expression of PSMB9/β1i was 
attributable to G871E somatic mutation in the ATP-binding region of 
JAK1 in SKN cell line, which is established from patient with U-LMS. 
It is furthermore likely that the PSMB9/β1i expressions are down-
regulated in human U-LMS tissues such like human U-LMS cell line. 
We demonstrate that there are serious mutational defects in the factors 
on the IFN-γ pathway, which is the key cell-signaling pathway for 
PSMB9/β1i expression and promoter region of PSMB9/β1i gene, in 
human U-LMS. The somatic mutational defects in the IFN-γ pathway 
may induce the initial development of U-LMS. Recent advances in our 
understanding of the biological characters of U-LMS have concentrated 
on the impaired IFN-γ pathway. It is clear that somatic mutations in 
key regulatory genes alter the behavior of cells and can potentially 
lead to the unregulated growth seen in malignant tumour. Therefore, 
continued improvement of our knowledge of the molecular biology of 
U-LMS may ultimately lead to novel therapies and improved outcome.
The effects of IFN-γ on expression of PSMB9/β1i was examined 
using five cell lines [13]. Expressions of PSMB9/β1i were not 
markedly induced by IFN-γ treatment in human U-LMS cell lines, 
although cervical epithelial adenocarcinoma cell lines and normal 
human uterus smooth muscle cells underwent strong induction 
of PSMB9/β1i following IFN-γ treatment [13]. Furthermore, the 
immunohistochemistry (IHC) experiments revealed a serious loss in 
the ability to induce expression of PSMB9/β1i in human U-LMS tissues 
in comparison with normal myometrium tissues located in same tissue 
sections and other 4 mesenchymal tumour types. Of 58 U-LMS, 50 
cases were negative for PSMB9/β1i, 4 cases were focally positive, 2 cases 
were weakly positive, and 2 cases were positive. IHC analyses showed 
positivity for Ki-67/MIB1 and differential expression of ESTROGEN 
RECEPTOR (ER), PROGESTERONE RECEPTOR (PR), TUMOUR 
PROTEIN 53 (TP53), and CALPONIN h1. In addition, the expression 
level of PSMB9/β1i was also examined in the skeletal muscle metastasis 
from U-LMS, the histological diagnosis was consistent with metastatic 
LMS for skeletal muscle lesions. Pathological study of surgical samples 
showed presence of a mass measuring 3 cm at largest diameter in 
lumbar quadrate muscle without a fibrous capsule. All lymph nodes 
were negative. In western blotting and RT-PCR experiments, PSMB9/
β1i was expressed in normal myometrium, LMA, and IFN-Γ-treated 
HeLa cells, but not in human U-LMS. The both research experiments 
strongly supported the research findings obtained from IHC 
experiments.
Most frequently, LMS have appeared in the uterus, retroperitoneum 
or extremities, and although histologically indistinguishable, they 
have different clinical courses and chemotherapeutic responses. The 
molecular basis for these differences remains unclear. Therefore, the 
examination of human U-LMS tissues (23 U-LMS tissue sections and 
normal tissue sections located in the same tissue) was performed to 
detect somatic mutations in the IFN-γ pathway, JAK1, JAK2, STAT1 
and promoter region of PSMB9/β1i gene (Figure 1). As the catalytic 
domains of these factors are most likely to harbour mutations that 
activate the gene product, we focused on stretches (exons) containing 
the kinase domains, transcriptional activation domains and enhancer/
promoter region. Over all, nearly 43.5% (10/23) of U-LMS tissues 
had serious mutations in the ATP binding region or kinase-specific 
active site of JAK1; furthermore, 43.5% (10/23) of U-LMS tissues had 
serious mutations in essential sites of the promoter region of PSMB9/
Figure 1. IFN-γ treatment markedly increased the expression of PSMB9/β1i, a subunit 
of the immunoproteasome, which alters the proteolytic specificity of proteasomes. After 
binding of IFN-γ to the type II IFN receptor, which is constructed by two components, 
IFN-γ receptor subunit 1 (IFNGR1) and IFN-γ receptor subunit 2 (IFNGR2), Janus-
activated kinase 1 (JAK1) and JAK2 are activated and phosphorylate the signal transducer 
and activator of transcription 1(STAT1) on the tyrosine residue at position 701 (Tyr701) 
and the serine residue at position 727 (Ser727) [32,33]. Tyrosine phosphorylated STAT1 
forms homodimers that translocate to the nucleus and bind GAS (IFN-γ-activated site) 
elements in the promoters of IFN-γ-regulated genes [32,33]. IFN-γ activated JAKs also 
regulate, through asyet unknown intermediates, activation of the catalytic subunit (p110) 
of phosphatidylinositol 3-kinase (PI3K). The activation of PI3K ultimately results 
in downstream activation of protein kinase C-δ (PKC-δ), which in turn regulates the 
phosphorylation of STAT1 on the Ser727. The phosphorylation of Ser727 is not essential for 
the translocation of STAT1 to the nucleus or for the binding of STAT1 to enhancer/promoter 
region of targeted DNA, but it is required for full transcriptional activation [34,35]. 
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β1i gene, which is required for transcriptional activation of PSMB9/
β1i gene (Table 1). No somatic mutation in essential sites, Tyr701 
and Ser727, which are required for STAT1 transcriptional activation, 
was elucidated in uterine LMS. Nearly 21.7% (5/23) of U-LMS tissues 
unexpectedly had mutations in the STAT1 intermolecular region, 
which is not yet reported to be important for biological function as 
transcriptional activation. No somatic mutation in the ATP-binding 
region and kinase-active site of JAK2 was detected in U-LMS (Table 1). 
MOTIF Search profiling [14] and NCBI’s Conserved Domain Database 
and Search Service, v2.17 analysis also revealed that somatic mutations, 
which were identified in the catalytic domains of these genes, resulted 
in impaired activations of tyrosine kinases or transcriptional factor [15].
In a recent report, a comparative genomic hybridization (CGH)-
based analysis of LMS using a high-resolution genome-wide array 
gave gene-level information about the amplified and deleted regions 
that may play a role in the development and progression of human 
U-LMS. Other reports showed that among the most intriguing changes 
in genes were losses of JAK1 (1p31-p32) and PSMB9/β1i (6p21.3) 
[16,17]. It has also been demonstrated that a correlation exists between 
the development of malignant tumours and ethnic background, so 
we conducted CGH experiments with tissue samples obtained from 
Japanese patients in order to obtain gene-level information. Our results 
showed that LMS having a clear functional loss at JAK1 (1p31-p32) 
and PSMB9/β1i (6p21.3) also harbored one nonsense mutation and 
one deletion, suggesting a possible homozygous loss of function. The 
discovery of these mutational defects in a key cell-signaling pathway 
may be important in understanding the pathogenesis of human U-LMS. 
Uterine LMS are relatively rare mesenchymal tumours, having 
an estimated annual incidence of 0.64 per 100 000 women. They 
account for approximately one-third of uterine sarcomas and 1.3% 
of all uterine malignancies. They are the disease with extremely poor 
prognosis, considering aggressive malignancies with a 5-year survival 
rate of only 50% for tumours confined to the uterus. At present, 
surgical intervention is virtually the only means of treatment for 
U-LMS [4-8]. Although adjuvant pelvic irradiation appears to decrease 
the rate of local recurrence, adjuvant therapy does not appear to 
significantly improve survival. Furthermore, gynecological cancer, 
for instance breast cancer and endometrial carcinomas, are strongly 
promoted by female hormones, but the rate of estrogen receptor and 
progesterone receptor expression is reported to be significantly less 
in human U-LMS compared with normal myometrium. These low 
receptor expressions were found to not correlate with the promotion 
of initial disease development or with the overall survival of patients 
with U-LMS; however, molecular targeting therapies against tumours 
have recently shown remarkable achievements [18]. To improve the 
prognosis of human U-LMS, research experiments were performed 
to identify the key role of pro- or anti-oncogenic factors that have 
an important function in their pathogenesis and that could serve as 
molecular targets for tumour treatment. For this purpose, several 
research facilities conducted a microarray procedure between human 
U-LMS and normal myometrium and showed that several known 
pro-oncogenic factors, such as brain-specific polypeptide PEP-19 and 
a transmembrane tyrosine kinase receptor, c-KIT, may be associated 
with the pathogenesis of human U-LMS [19-21]. However, in terms 
of the tumourigenesis of human U-LMS, merely comparing the 
expression of potential pro-oncogenic factors between normal and 
malignant tissues is not sufficient because the results obtained may 
be the consequence of malignant transformation and, therefore, 
not necessarily the cause. In addition, dysregulation of apoptotic 
mechanisms has also been implicated in many human malignancies. 
Although the significant differential expression of apoptotic and cell 
cycle regulatory factors in human U-LMS, such as B-cell Lymphoma-2 
(BCL-2), BCL-2-Associated X protein (BAX), P16 Inhibits CDK4 
(P16/INK4a), P21 Cyclin-Dependent Kinase Inhibitor 1 (P21/CIP1), 
P27 Kinase Inhibitor Protein 1 (P27/KIP1), Cellular v-KIT Hardy-
Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (c-KIT), 
Mitogen-Inducible Gene-2 (MIG-2), MDM2, TUMOUR PROTEIN 53 
(TP53), have all been reported and compared to normal myometrium, 
there exists no scientific evidence to show that abnormal expression 
Mutations in the IFN-y pathway in human uterine Ieiomyosarcoma
Gene Name Locus GenBank Accession MIM ID Tumor Nucleotide Amino Acid Domain Evolutionary 
conservation
JAK1 HUMPTKJAK1 M64174.1 *147795 ULMS G2612A 
G2618A
G2626A 
G2642T
G2643A 
A2957C
A2960C 
A2985T
G781E 
G873D
G876R 
C881F
C881 Stop Q986P
Y987S 
R995S
ATP binging 
ATP binding
ATP binging 
ATP binging
ATP binding 
active site
active site 
active site
p,c,m,r,g,d
JAK2 AF005216 AF005216.1 +147796 ULMS ND2 ND ND p,c,b,m,r,g,d
STAT1 NM_007315 NM_007315 +600555 ULMS A2104C
T2128G 
T2078G
A2148C
1702E
S710A 
L693R
R7168
NA3
NA 
NA
NA
c,b,m,r,g,d
PSMB91 X62741 X62741.1 *177045 ULMS A209T
A210G 
C213A
C214T 
G215A
A216G 
A217G
G219 A 
G239 A
RF-E site
RF-E site 
RF-E site
RF-E site 
RF-E site
RF-E site 
RF-E site
RF-E site  
HSF site
1LMP2 promoter region, NCBI Reference Sequence NT_007592.15 Homo sapiens Chromosome 62not detected 3non-kinaseactivation region 4Evolutionary conservation refers to the species 
in which an identical residue was observed in the homolog (p, pan troglodytes; c, canis lupus familiaris; b, bostaurus; m, musmusculus; r, rattusnorvegicus; g, gallusgallus; d, danio rerio)
Table 1. Somatic mutations in IFN-γsignaling pathway in human uterine leiomyosarcoma. The data of somatic mutations in table 1 was shown separately with respect to each gene, JAK1, 
JAK2, STAT1 and activation region of the promoter of PSMB9/β1i gene.
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of these factors directly correlates to the initiation and promotion of 
human U-LMS. PSMB9/β1i-dificient mice were reported to be prone 
to the development of U-LMS, but not in their parental mice, C57BL/6 
mice [12]. The percentage of mice with overt tumours increased 
with age after six months, with a cumulative prevalence of disease in 
female mice of 37% by 14 months of age and no apparent plateau at 
this late observation time. Histopathological examinations of PSMB9/
β1i-deficient uterine neoplasms revealed common characteristic 
abnormalities of U-LMS. In addition, recent research reports show the 
loss in the IFN-Γ-inducible ability of PSMB9/β1i expressions in SKN 
cell line and other primary U-LMS cells established from patients. 
The histopathological experiments demonstrated a serious loss in the 
ability to induce the expression of PSMB9/β1i in human U-LMS tissues 
in comparison with normal myometrim tissues located in same tissue 
sections. 
IFN-Γ treatment markedly increased the expression of PSMB9/β1i, 
a subunit of the proteasome, which alters the proteolytic specificity of 
proteasomes. Sequence analysis demonstrated that the loss of IFN-γ 
responsiveness in the human U-LMS cell line was attributable to the 
inadequate kinase activity of JAK1 due to a G781E somatic mutation 
in the ATP-binding region [13]. The defect was localized to JAK1 
activation, which acts upstream in the IFN-γ signal pathway since 
IFN-γ treatment could not strongly induce JAK1 kinase activity in 
human U-LMS cell lines. Genetic alterations in tyrosine kinases have 
previously been firmly implicated in tumourigenesis, but only a few 
serine/threonine kinases are known to be mutated in human cancers 
[22-25]. For instance, mice carring homozygous deletion of Phosphatase 
and Tensin Homolog Deleted from Chromosome 10 (Pten) alleles 
developed widespread SMC hyperplasia and abdominal LMS [26], and 
JUN oncogene amplification and over-expression block adipocytic 
differentiation in highly aggressive sarcomas. Most frequently, LMS 
have appeared in the uterus, retroperitoneum or extremities, and 
although histologically indistinguishable, they have different clinical 
courses and chemotherapeutic responses. The molecular basis for these 
differences remains unclear, therefore, the examination of human 
uterine LMS tissues (23 LMS tissue sections and normal tissue sections 
located in the same tissue) was performed to detect somatic (tumour-
specific) mutations in the IFN-γ signal molecules. In a recent report, 
high-resolution genome wide array comparative genomic hybrydization 
(CGH) analysis of LMS cases gave gene-level information about the 
amplified and deleted regions that may play a role in the development 
and progression of human U-LMS. Among the most intriguing genes, 
whose copy number sequence was revealed by CGH, were loss of JAK1 
(1p31-p32) and PSMB9/β1i (6p21.3) [16,17]. The discovery of these 
mutational defects in a key cell-signaling pathway may be an important 
development in the pathogenesis of human U-LMS.
The growth of JAK1-deficient cell lines reportedly is unaffected; 
similarly, the cell cycle distribution pattern of freshly explanted tumour 
cells derived from JAK1-deficient tumours shows no response to 
IFN-γ signaling [27]. The growth of the original SKN cells, which had 
defective JAK1 activity, was unaffected by IFN-γ treatment. In contrast, 
the growth of JAK1-transfected SKN cells, which had strong exogenous 
JAK1 activity, was prevented by IFN-Γ treatment. Interestingly, when 
PSMB9/β1i-transfected SKN cells, which have marked the expression 
of PSMB9/β1i, were analyzed, expression of exogenous PSMB9/β1i 
resulted in cell growth inhibition. Conversely, the growth of PSMB9/
β1i-transfected SKN cells was unaffected by IFN-Γ signal pathway. 
Taken together, IFN-γ response to cell growth inhibition may be 
attributable to the physiological significance of PSMB9/β1i. 
In conclusion, the down regulation of major histocompatibility 
complex (MHC) expression, including the TAP1 and PSMB9/β1i 
genes, is one of the biological mechanisms tumour cells use to evade 
host immunosurveillance [28-30]. Recently, the incidence of IFN-γ 
unresponsiveness in human tumours was examined in several cancers, 
and revealed that approximately 33% of each group exhibited a reduction 
in IFN-γ sensitivity [31]. Nevertheless, the expression of PSMB9/β1i, 
rather than providing an escape from immune surveillance, seems to 
play an important role in the negative regulation of human U-LMS cell 
growth. Defective expression of PSMB9/β1i is likely to be one of the 
risk factors for the development of human uterine neoplasm, as it is in 
the PSMB9/β1i-deficient mouse. Thus, gene therapy with PSMB9/β1i 
expression vectors may be a new treatment for U-LMS that exhibits 
a defect in the expression of PSMB9/β1i. Because there is no effective 
therapy for unresectable U-LMS, our results may bring us to specific 
molecular therapies to treat this disease.
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